RSNA Education Exhibits

PET/CT of Esophageal Cancer: Its Role in Clinical Management

Published Online:Nov 1 2007https://doi.org/10.1148/rg.276065742

Abstract

Positron emission tomography (PET)/computed tomography (CT) has important utility and limitations in the initial staging of esophageal cancer, evaluation of response to neoadjuvant therapy, and detection of recurrent malignancy. Esophageal cancer is often treated by using a combined modality approach (chemotherapy, radiation therapy, and esophagectomy); correct integration of PET/CT into the conventional work-up of esophageal cancer requires a multidisciplinary approach that combines the information from PET/CT with results of clinical assessment, diagnostic CT, endoscopic gastroduodenoscopy, and endoscopic ultrasonography. PET/CT has limited utility in T staging of esophageal cancer and relatively limited utility in detection of dissemination to locoregional lymph nodes. However, PET/CT allows detection of metastatic disease that may not be identifiable with other methods. PET/CT is not sufficiently reliable in the individual patient for determination of treatment response in the primary tumor. Interpretation of PET/CT results is optimized by understanding the diagnostic limitations and pitfalls that may be encountered, together with knowledge of the natural history of esophageal cancer and the staging and treatment options available.

References

1 JemalA, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin2006; 56: 106–130. Crossref, Medline, Google Scholar
2 FlanaganFL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol1997; 168: 417–424. Crossref, Medline, Google Scholar
3 RothJA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg1988; 96: 242–248. Crossref, Medline, Google Scholar
4 UrbaSG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol2001; 19: 305–313. Crossref, Medline, Google Scholar
5 KelsenDP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med1998; 339: 1979–1984. Crossref, Medline, Google Scholar
6 ForastiereAA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol1993; 11: 1118–1123. Crossref, Medline, Google Scholar
7 DoningtonJS, Miller DL, Allen MS, Deschamps C, Nichols FC 3rd, Pairolero PC. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg2003; 24: 631–636; discussion 636–637. Crossref, Medline, Google Scholar
8 AnconaE, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer2001; 91: 2165–2174. Crossref, Medline, Google Scholar
9 SwisherSG, Hunt KK, Holmes EC, Zinner MJ, McFadden DW. Changes in the surgical management of esophageal cancer from 1970 to 1993. Am J Surg1995; 169: 609–614. Crossref, Medline, Google Scholar
10 SwisherSG, Ajani JA, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys2003; 57: 120–127. Crossref, Medline, Google Scholar
11 Medical Research Council Esophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727–1733. Crossref, Medline, Google Scholar
12 BruzziJF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer2007; 109: 125–134. Crossref, Medline, Google Scholar
13 LiberaleG, Van Laethem JL, Gay F, et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol2004; 30: 942–947. Crossref, Medline, Google Scholar
14 FlamenP, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg2000; 120: 1085–1092. Crossref, Medline, Google Scholar
15 FlamenP, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000; 18: 3202–3210. Crossref, Medline, Google Scholar
16 van WestreenenHL, Heeren PA, van Dullemen HM, et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg2005; 9: 54–61. Crossref, Medline, Google Scholar
17 LuketichJD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg1999; 68: 1133–1136; discussion 1136–1137. Crossref, Medline, Google Scholar
18 SwisherSG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer2004; 101: 1776–1785. Crossref, Medline, Google Scholar
19 SwisherSG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg2004; 78: 1152–1160; discussion 1152–1160. Crossref, Medline, Google Scholar
20 WesterterpM, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology2005; 236: 841–851. Link, Google Scholar
21 WeberWA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol2001; 19: 3058–3065. Crossref, Medline, Google Scholar
22 WiederHA, Beer AJ, Lordick F, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med2005; 46: 2029–2034. Medline, Google Scholar
23 GreeneF, Fritz A, Balch C, et al. Esophagus. In: Greene F, Fritz A, Balch C, et al, eds. AJCC cancer staging handbook part III: digestive system 9—esophagus. 6th ed. New York, NY: Springer-Verlag, 2002. Google Scholar
24 DeMeesterSR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol2006; 13: 12–30. Crossref, Medline, Google Scholar
25 IizukaT, Isono K, Kakegawa T, Watanabe H. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases. Chest1989; 96: 1005–1011. Crossref, Medline, Google Scholar
26 KorstRJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg1998; 115: 660–669; discussion 669–670. Crossref, Medline, Google Scholar
27 LoweVJ, Booya F, Fletcher JG, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol2005; 7: 422–430. Crossref, Medline, Google Scholar
28 RoschT. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am1995; 5: 537–547. Crossref, Medline, Google Scholar
29 RiceTW, Blackstone EH, Adelstein DJ, et al. Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg2003; 125: 1091–1102. Crossref, Medline, Google Scholar
30 CerfolioRJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg2005; 129: 1232–1241. Crossref, Medline, Google Scholar
31 BruzziJF, Truong MT, Marom EM, et al. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol2006; 187: 1116–1123. Crossref, Medline, Google Scholar
32 AkiyamaH, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg1981; 194: 438–446. Crossref, Medline, Google Scholar
33 ClarkGW, Peters JH, Ireland AP, et al. Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma. Ann Thorac Surg1994; 58: 646–653; discussion 653–654. Crossref, Medline, Google Scholar
34 RubinE, Farber J. The esophagus. In: Rubin E, Farber J, eds. Pathology. 2nd ed. Philadelphia, Pa: Lippincott, 1994; 629. Google Scholar
35 EloubeidiMA, Wallace MB, Hoffman BJ, et al. Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography. Ann Thorac Surg2001; 72: 212–219; discussion 219–220. Crossref, Medline, Google Scholar
36 HieleM, De Leyn P, Schurmans P, et al. Relation between endoscopic ultrasound findings and outcome of patients with tumors of the esophagus or esophagogastric junction. Gastrointest Endosc1997; 45: 381–386. Crossref, Medline, Google Scholar
37 LerutT, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg2000; 232: 743–752. Crossref, Medline, Google Scholar
38 van WestreenenHL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004; 22: 3805–3812. Crossref, Medline, Google Scholar
39 RiceTW. Clinical staging of esophageal carcinoma: CT, EUS, and PET. Chest Surg Clin N Am2000; 10: 471–485. Medline, Google Scholar
40 HeerenPA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med2004; 45: 980–987. Medline, Google Scholar
41 CroftDR, Trapp J, Kernstine K, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer2002; 36: 297–301. Crossref, Medline, Google Scholar
42 MackieGC, Pohlen JM. Mediastinal histoplasmosis: F-18 FDG PET and CT findings simulating malignant disease. Clin Nucl Med2005; 30: 633–635. Crossref, Medline, Google Scholar
43 AlaviA, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med2002; 32: 293–321. Crossref, Medline, Google Scholar
44 MaedaJ, Ohta M, Hirabayashi H, Matsuda H. False positive accumulation in 18F fluorodeoxy-glucose positron emission tomography scan due to sarcoid reaction following induction chemotherapy for lung cancer. Jpn J Thorac Cardiovasc Surg2005; 53: 196–198. Crossref, Medline, Google Scholar
45 LightdaleCJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol2005; 23: 4483–4489. Crossref, Medline, Google Scholar
46 SteupWH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction: long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg1996; 111: 85–94; discussion 94–95. Crossref, Medline, Google Scholar
47 RothJA, Putnam JB Jr, Rich T, Forastiere AA. Cancer of the esophagus. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. New York, NY: Lippincott-Raven, 1997; 980–1021. Google Scholar
48 QuintLE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer1995; 76: 1120–1125. Crossref, Medline, Google Scholar
49 BruzziJF, Truong MT, Macapinlac H, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol2007; 36: 21–29. Crossref, Medline, Google Scholar
50 van WestreenenHL, Westerterp M, Jager PL, et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med2005; 46: 1321–1325. Medline, Google Scholar
51 KumagaiY, Kawano T, Nakajima Y, et al. Multiple primary cancers associated with esophageal carcinoma. Surg Today2001; 31: 872–876. Crossref, Medline, Google Scholar
52 BergerAC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol2005; 23: 4330–4337. Crossref, Medline, Google Scholar
53 WalshTN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med1996; 335: 462–467. Crossref, Medline, Google Scholar
54 UrschelJD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg2003; 185: 538–543. Crossref, Medline, Google Scholar
55 FioricaF, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut2004; 53: 925–930. Crossref, Medline, Google Scholar
56 LawS, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg1997; 114: 210–217. Crossref, Medline, Google Scholar
57 DowneyRJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol2003; 21: 428–432. Crossref, Medline, Google Scholar
58 FlamenP, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol2002; 13: 361–368. Crossref, Medline, Google Scholar
59 WiederHA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol2004; 22: 900–908. Crossref, Medline, Google Scholar
60 KroepJR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer: a comparison of different analytical methods. Mol Imaging Biol2003; 5: 337–346. Crossref, Medline, Google Scholar
61 BrucherBL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg2001; 233: 300–309. Crossref, Medline, Google Scholar
62 KatoH, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg2002; 184: 279–283. Crossref, Medline, Google Scholar
63 ErasmusJJ, Munden RF, Truong MT, et al. Pre-operative chemoradiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated CT-PET imaging. J Thorac Oncol2006; 1: 478–486. Crossref, Medline, Google Scholar
64 PanT, Mawlawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med2005; 46: 1481–1487. Medline, Google Scholar
65 NehmehSA, Erdi YE, Pan T, et al. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys2004; 31: 1333–1338. Crossref, Medline, Google Scholar
66 HautzelH, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. Google Scholar

Article History

Published in print: Nov 2007

Vol. 27, No. 6

Metrics

Altmetric Score

PDF download